Opko Health, a New York-listed pharmaceutical company, has made a strategic investment of undisclosed size in BioZone Pharmaceuticals and acquired the rights to its drug delivery platforms.
Opko gained a worldwide license from BioZone to develop and commercialize QuSomes, a skin care product, and an enhanced formulation of Propofol, which is used for anesthesia and sedation.